ARTES Biotechnology ^Company

ARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine candidates on its Virus-Like Particle (VLP) based platform technologies METAVAX® and SplitCore. METAVAX® is the biotech’s proprietary platform for vaccine development built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles (cVLPs) are introduced as antigen presentation carriers without the intervention of host lipid membrane structures.

The ARTES Biotechnology development strategy is optimised to present domains of the SARS-CoV-2 spike protein, with or without an antigen derived from the nucleocapsid protein of the virus, on the VLPs (METAVAX®) and cVLPs (SplitCore) surface. Dr. Michael Piontek, Managing Director of ARTES says: “The battle against the COVID-19 pandemic will require a lot of different innovative approaches. We are convinced that our technology platform can provide on short term an important contribution in this global combat. The compelling advantage of our technology is the cost-effective production of efficacious and safe vaccines in a platform already applied in mass vaccination programs.”